MedTrace Logo

Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer

NCT04249440 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1067

Last updated 2020-09-28

No results posted yet for this study

Summary

Preoperative systemic treatment can make patients getting more opportunity for breast-conserving surgery, down-staging and new drugs developing. It is particularly common in human epidermal growth factor receptor 2 (HER2)-over expressing subtype for as high as 40%\~60% pCR rate of such a population. Even though, in NSABP B18/27 trials, it had been proved that PST could not improve either disease-free survival (DFS) or overall survival (OS) comparing with postoperatively systemic treatment in total population. We designed a real-world study to investigate the prognosis of anti-HER2 treatment combined with chemotherapy preoperatively versus postoperatively in HER2-positive early breast cancer

Conditions

Interventions

PROCEDURE

Preoperative systemic treatment

neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Xingfei Yu, M.D. · Zhejiang Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2019-12-30
Completion
2020-03-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249440 on ClinicalTrials.gov